UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 13,465 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 11.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 101,900 shares of the company’s stock after selling 13,465 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.24% of Kyverna Therapeutics worth $498,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of KYTX. Deerfield Management Company L.P. Series C increased its stake in shares of Kyverna Therapeutics by 35.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 1,983,000 shares of the company’s stock valued at $14,872,000 after buying an additional 520,663 shares during the period. Novo Holdings A S increased its position in Kyverna Therapeutics by 5.7% during the 3rd quarter. Novo Holdings A S now owns 1,850,000 shares of the company’s stock valued at $9,046,000 after purchasing an additional 100,000 shares during the period. Millennium Management LLC raised its holdings in Kyverna Therapeutics by 32.8% in the 2nd quarter. Millennium Management LLC now owns 923,082 shares of the company’s stock worth $6,923,000 after purchasing an additional 227,988 shares in the last quarter. Great Point Partners LLC lifted its position in shares of Kyverna Therapeutics by 232.8% in the 2nd quarter. Great Point Partners LLC now owns 499,152 shares of the company’s stock worth $3,744,000 after purchasing an additional 349,152 shares during the period. Finally, MBB Public Markets I LLC bought a new stake in shares of Kyverna Therapeutics during the 2nd quarter valued at about $3,076,000. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on KYTX. RODMAN&RENSHAW upgraded Kyverna Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 9th. HC Wainwright reduced their target price on shares of Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 20th. Wells Fargo & Company decreased their price target on shares of Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, November 15th. UBS Group assumed coverage on shares of Kyverna Therapeutics in a research note on Thursday, October 10th. They set a “buy” rating and a $13.00 price objective on the stock. Finally, Rodman & Renshaw assumed coverage on shares of Kyverna Therapeutics in a research note on Wednesday, October 9th. They set a “buy” rating and a $16.00 target price for the company. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $25.71.

Kyverna Therapeutics Trading Up 3.4 %

NASDAQ KYTX opened at $4.00 on Friday. The stock has a 50 day moving average price of $4.93 and a 200-day moving average price of $6.89. Kyverna Therapeutics, Inc. has a one year low of $3.63 and a one year high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings data on Wednesday, November 13th. The company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.01. The firm had revenue of $0.01 million for the quarter. On average, sell-side analysts predict that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current fiscal year.

Kyverna Therapeutics Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.